The treatment options for psoriasis in Brazil have changed remarkably due to the growth of the nation's public healthcare system Sistema Único de Saúde SUS, which is crucial for enhancing diagnosis and access to skin care. The growth of public healthcare has led to more dermatology appointments, screening efforts, and treatment access, especially in cities and areas that were previously neglected where psoriasis often went undiagnosed. Campaigns led by the government to raise awareness, along with training programs for doctors, have improved the identification of moderate-to-severe psoriasis, leading to more timely interventions and organized treatment methods. Primary healthcare facilities now serve as the first step for dermatological referrals, while specialized medical facilities and university hospitals manage complicated cases that need systemic treatments or biologics. Despite ongoing gaps between urban and rural areas, teledermatology initiatives and digital health solutions have expanded access to specialist consultations for patients in distant locations, enhancing outcomes and decreasing treatment wait times. The establishment of national clinical guidelines has made care procedures more uniform, encouraging evidence-based treatment progression from topical options to systemic medications and advanced biologics when necessary.

Financial support from the government has also made it possible to access phototherapy devices and chronic disease management initiatives, which allow for ongoing follow-up for patients suffering from severe psoriasis. Partnerships between public agencies and academic research institutions have bolstered clinical research capabilities, enabling Brazil to join international trials and quickly implement new treatment approaches. The growth of Brazil’s public healthcare system has significantly improved access to diagnosis and treatment for psoriasis, creating a solid basis for better disease management and wider use of modern therapies among various patient groups.According to the research report, " Brazil Psoriasis Treatment Market Overview, 2031," published by Bonafide Research, the Brazil Psoriasis Treatment market is anticipated to grow at more than 9.39% CAGR from 2026 to 2031. Brazil is one of the largest markets for psoriasis treatments in Latin America, supported by its significant population, growing healthcare system, and the rising rate of chronic inflammatory illnesses. The country’s robust local pharmaceutical manufacturing industry is essential in providing topical solutions, systemic medications, and a broadening range of biosimilars aimed at making treatments more affordable. Government buying programs and centralized procurement strategies seek to manage expenses while guaranteeing access to vital medicines, especially in the public health sector. Nonetheless, the cost of biologics is a major hurdle, as advanced treatments can burden public health budgets and have strict qualifications for reimbursement.

The sensitivity to prices among healthcare professionals and patients has heightened the demand for domestically produced biosimilars and affordable treatment options. Brazil's regulatory framework promotes collaborations between international pharmaceutical firms and local producers, fostering technology transfer and enhancing local production abilities. There are growing opportunities emerging from government-driven procurement strategies, which create stable demand for manufacturers that can satisfy pricing and quality requirements. Furthermore, pharmaceutical companies are looking into creative distribution methods and programs for patient support to enhance compliance and treatment results. The expanding biotechnology landscape in Brazil is focusing on immunology research and clinical studies, establishing the nation as a regional center for therapeutic advancements. With a rising government emphasis on managing chronic diseases and promoting healthcare equity, the market holds strong potential for the growth of biosimilars, local manufacturing of advanced therapies, and wider integration of contemporary treatment methods.

Brazil psoriasis treatment market by type is divided into plaque psoriasis, psoriatic arthritis and others. The Brazilian psoriasis treatment market is mainly influenced by plaque psoriasis, which represents the highest percentage of diagnosed cases and is the primary factor driving demand in both public and private dermatological facilities. The growth of Brazil's public health system SUS and heightened public awareness of dermatological conditions have led to earlier diagnoses, enabling doctors to start treatment quickly and limit disease progression. Public hospitals and university clinics handle a considerable number of patients, particularly in major cities like São Paulo and Rio de Janeiro, where specialized dermatology centers are readily available. Psoriatic arthritis is becoming more acknowledged as a significant coexisting condition, fostering greater collaboration between dermatologists and rheumatologists. Enhanced screening protocols and advancements in imaging technologies have facilitated the earlier identification of joint issues, resulting in an increased application of systemic therapies and biologics in integrated care environments.

The growing occurrence of metabolic conditions and an aging demographic contribute to the expansion of this segment. The others category, which includes guttate, pustular, and erythrodermic psoriasis, is smaller but more complex, often necessitating hospital-based treatments and intricate management strategies. These severe forms create a demand for biologics, phototherapy devices, and specialized inpatient care. Variations in healthcare services affect access to advanced treatments, particularly in rural and low-income regions. Nevertheless, telemedicine initiatives and outreach programs are enhancing diagnosis and referral systems across the nation. The segmentation of Brazil's psoriasis market shows a large population suffering from plaque psoriasis, increasing clinical focus on psoriatic arthritis, and the need for specialized care for serious subtypes, all shaped by improved public healthcare access and rising awareness of inflammatory skin disorders.Brazil psoriasis treatment market by treatment type is divided into biologics drugs, systemic drugs, topical drugs, phototherapy and others.

Brazil’s market for psoriasis treatment, segmented by type of therapy, illustrates a bi-level healthcare system where worries about public sector affordability exist alongside advancements in the private sector. Topical medications are the most commonly prescribed initial treatment, especially in the SUS framework, as they are cost-effective and accessible through public pharmacies. Corticosteroids and vitamin D derivatives are frequently recommended for cases of mild to moderate severity. Systemic treatments, such as methotrexate and cyclosporine, retain a considerable share in the market for moderate to severe psoriasis since they are relatively low-cost and included in national treatment protocols. Nevertheless, biologic therapies represent the fastest-growing area, fueled by the rising availability of biosimilars and government efforts to improve access to innovative treatments. Urban hospitals and private healthcare providers have been faster in adopting new biologics, while public health organizations are slowly introducing affordable biosimilar options through centralized procurement strategies.

Phototherapy remains an essential non-drug treatment, especially in specialized dermatology facilities that offer ultraviolet treatment for patients who either cannot access biologics or opt for non-systemic solutions. The others category, which includes new oral small-molecule treatments and combination therapy plans, is gaining traction as pharmaceutical firms increase research and roll out innovative products for Latin American demographics. Cost-effectiveness remains a crucial element affecting treatment choices, with both public and private sectors striving for budget-friendly options that ensure clinical efficacy. Brazil’s treatment segmentation showcases a transitional market where conventional therapies are still vital, while biosimilars and advanced biologics progressively change the treatment scene.Brazil psoriasis treatment market by distribution channel is divided into hospital pharmacies, retail pharmacies and e-commerce. The distribution of psoriasis treatments in Brazil is influenced by a mix of public health systems, private pharmacy chains, and the rise of digital health platforms. Hospital pharmacies are pivotal in providing biologics and advanced systemic treatments, especially within SUS facilities and specialized dermatology clinics catering to moderate to severe cases.

Government-funded procurement initiatives and centralized buying agreements enable hospitals to offer expensive medications to qualifying patients, ensuring they have access while managing healthcare costs. Retail pharmacies serve as the primary source for topical therapies, maintenance medications, and oral systemic drugs prescribed at outpatient facilities. Brazil’s vast collection of private and chain pharmacies ensures easy access to medications in urban and suburban areas, though availability can be inconsistent in rural regions with fewer healthcare resources. Pharmacists also significantly contribute to patient education and support with adherence for chronic illnesses like psoriasis. The e-commerce sector is rapidly growing as Brazil witnesses an increase in digital health adoption and online pharmacy services. More consumers are turning to online platforms for refills, dermatological products, and telehealth follow-up visits, although strict regulatory guidelines still apply to prescription medications.

Digital pharmacies are especially favored by younger urban patients who value convenience and remote healthcare access. The integration of electronic prescriptions and telemedicine is poised to further enhance online distribution channels. Brazil’s distribution model showcases a hospital-focused approach for advanced treatments backed by an extensive retail pharmacy network and a swiftly changing e-commerce framework that improves accessibility and convenience for managing chronic conditions. Considered in this report* Historic Year: 2020* Base year: 2025* Estimated year: 2026* Forecast year: 2031Aspects covered in this report* Psoriasis Treatment Market with its value and forecast along with its segments* Various drivers and challenges* On-going trends and developments* Top profiled companies* Strategic recommendationBy TypePlaque PsoriasisPsoriatic ArthritisOthersBy Treatment TypeBiologics DrugsSystemic DrugsTopical DrugsPhototherapyOthersBy Distribution ChannelHospital PharmaciesRetail Pharmaciese-Commerce.